

Document Type	I	Form
Index Number	I	Registry 131
Version Number	I	1.0
Title	Ι	Chronic Leukaemias
Author	Ι	Annelot van Amerongen
Authorised By	Ι	Annelot van Amerongen
Authorised On	Ι	22-Aug-2023
Release Date:		22-Aug-2023



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

CHRONIC LEUKAEMIAS

DISEASE

Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested. Consult the manual for further information.

Date of diagnosis: _ _ _ / _ _ (YYYY/MM/DD)

Classification:

- Chronic myeloid leukaemia (CML)
- Chronic lymphoid leukaemia (CLL)
- Prolymphocytic (PLL) and other chronic leukaemias



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ (YYYY/MM/DD)

Chronic Myeloid Leukaemias (CML)

CHROMOSOME ANALYSIS				
Chromosome analysis done before treatment (all methods including FISH): (Describe results of the most recent complete analysis)				
Not done or failed				
Yes, abnormal results: number of abno	ormalities present:	_		
Yes, normal results				
Unknown				
Date of chromosome analysis (if tested)://(YY	YY/MM/DD)		
Indicate below whether the abnormalities	were absent, present or	r not evaluated.		
t(9;22)	Absent	Present	Not evaluated	
trisomy 8	Absent	Present	Not evaluated	
extra Ph	Absent	Present	Not evaluated	
i(17)	Absent	Present	Not evaluated	
-7/Del	Absent	Present	Not evaluated	
3q26	Absent	Present	Not evaluated	
Other; specify:	Absent	Present		

OR

Transcribe the complete karyotype: ____



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

MOLECULAR MARKER ANALYSIS

Molecular markers analysis done before treatment:

🗌 No

Yes

Unknown

Indicate below whether the markers were absent, present or not evaluated.

ASXL1	Absent	Present	☐ Not evaluated
BCORL1	Absent	Present	☐ Not evaluated
BCR-ABL1	Absent	Present	☐ Not evaluated
CBFB-MYH11	Absent	Present	Not evaluated
EZH2	Absent	Present	Not evaluated
IDH1	Absent	Present	Not evaluated
IKZF1	Absent	Present	Not evaluated
KMT2D	Absent	Present	Not evaluated
RUNX1	Absent	Present	Not evaluated
SETD1B	Absent	Present	Not evaluated
TET2	Absent	Present	Not evaluated
TP53	Absent	Present	Not evaluated
Other; specify:	Absent	Present	

PREVIOUS THERAPIES

(between diagnosis and HCT/CT)

Previous therapies between diagnosis and the HCT/CT:

complete for each treatr	nent inte.	
Line of treatment	Drug	Start date (YYYY/MM/DD)
1	🔲 Imatinib 🔲 Nilotinib 🗌 Dasatinib 🗌 Bosutinib	
-	Ponatinib Asciminib Other drug, specify:	''
2	🔲 Imatinib 🔲 Nilotinib 🗌 Dasatinib 🗌 Bosutinib	
	Ponatinib Asciminib Other drug, specify:	///
2	🔲 Imatinib 🗌 Nilotinib 🗌 Dasatinib 🗌 Bosutinib	
3	Ponatinib Asciminib Other drug, specify:	////

*Please consult the LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS on the EBMT website for drugs/regimens names



Treatment Type	🗌 нст 🔲 ст	🗌 IST	Other

Treatment Date _ _ _ / _ / _ _ (YYYY/MM/DD)

Chronic Lymphocytic Leukaemias (CLL)

DISEASE

Sub-Classification:	
Chronic lymphocytic leukaemia (CLL) / small	lymphocytic lymphoma
Richter's syndrome:	
Transformed from a previous known CLL:	No: Primary Richter
	Yes: Date of original CLL diagnosis:/ (YYYY/MM/DD)
Type of Richter:	Hodgkin
	Other; specify:
Richter clonally related to CLL:	No
	Yes

CHROMOSOME ANALYSIS

Chromosome analysis done before treatment: (all methods includin (Describe results of the most recent complete analysis)	ng FISH):
Not done or failed	
Yes, abnormal results: number of abnormalities present:	
Yes, normal results	
Unknown	
Date of chromosome analysis <i>(if tested)</i> :/// (YYYY/ Indicate below whether the abnormalities were absent, present or no	
Trisomy 12	🗌 Absent 🔲 Present 🔲 Not evaluated
del(13q14)	🗌 Absent 🔄 Present 📋 Not evaluated
del(11q22-23)	🔲 Absent 🔄 Present 🔲 Not evaluated
del(17p)	🗌 Absent 📋 Present 📋 Not evaluated
Other; specify:	🗋 Absent 📋 Present
OR Transcribe the complete karyotype:	
Index: Registry 131 Title: Chronic Leukaemias Version: 1.0 Effectiv	e Date: 2023-08-22 THIS IS AN UNCONTOLLED COPY

	\frown	
(EBMT	
	-	

MOLECULAR MARKER ANALYSIS

Molecular markers analysis done before treatment:				
□ No				
☐ Yes				
IGVH mutational status: Absent Present; High risk subset? No Yes				
Indicate below whether the markers were absent, present or not evaluated.				

TP53 mutations	Absent Present Not evaluated
Other; specify:	Absent Present

PREVIOUS THERAPIES
(between diagnosis and HCT/CT)

Previous therapy lines before the HCT/CT:

🗌 No

Yes (complete the table below)

Line of treatment	Chemo/regimen used*	Treatment start date (YYYY/MM/DD)	Treatment end date (YYYY/MM/DD)	Reason for treatment withdrawal
				Planned withdrawal
				Toxicity
1		//	/ /	Progression or insufficient response
			Date unknown	☐ Other reason
				🗌 Unknown
				Planned withdrawal
				Toxicity
2		//	/ /	Progression or insufficient response
			Date unknown	☐ Other reason
				Unknown
				Planned withdrawal
				Toxicity
3		//	/ /	Progression or insufficient response
			Date unknown	Other reason
				Unknown
				Planned withdrawal
				Toxicity
4		//	/ /	Progression or insufficient response
			Date unknown	☐ Other reason
				🔲 Unknown

*Please consult the LIST OF CHEMOTHERAPY DRUGS/AGENTS AND REGIMENS on the EBMT website for drugs/regimens names Index: Registry 131 | Title: Chronic Leukaemias | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY



Treatment Type	🗌 нст 🔲 ст	IST Other
Treatment Date _	//(YY	YY/MM/DD)

Prolymphocytic (PLL) and Other Chronic Leukaemias

DISEASE

Sub-Classification: Prolymphocytic and other chronic leukaemias

Prolymphocytic leukaemia (PLL)	
PLL; B-cell	
PLL; T-cell	

Hairy cell leukaemia

Hairy cell leukaemia variant (atypic)

Other chronic leukaemia; specify:

CHROMOSOME ANALYSIS - only applicable for PLL

Chromosome analysis done before treatment (all methods including FISH):

(Describe results of the most recent complete analysis)

 $\hfill\square$ Not done or failed

Yes, abnormal results: number of abnormalities present:

Yes, normal results

Unknown

Date of chromosome analysis (if tested): ____/ __/ (YYYY/MM/DD)

Indicate below whether the abnormalities were absent, present or not evaluated.

inv(14)/ t(14;14)(q11;q32)	🗌 Absent 📋 Present 📄 Not evaluated
del(14)(q12)	🗌 Absent 📋 Present 📋 Not evaluated
t(11;14)(q23;q11)	🗋 Absent 📋 Present 📋 Not evaluated
t(7;14)(q35;q32.1)	🗌 Absent 📋 Present 📋 Not evaluated
t(X;14)(q35;q11)	🗋 Absent 📋 Present 📋 Not evaluated
idic(8)(p11)	🗌 Absent 📋 Present 📋 Not evaluated
del(17p)	🗋 Absent 📋 Present 📋 Not evaluated
Other; specify:	Absent Present

OR

Transcribe the complete karyotype: ____

(EBM	Т

Treatment Type	🗌 нст 🗌 ст	IST Other
Treatment Date _	//(YY	YY/MM/DD)

IMMUNOPHENOTYPING

only applicable for T-cell PLL

Immunophenotype of T-cells at diagnosis:

Note: Terminal desoxynucleotidyl transferase (TdT) must be negative.

No

Yes
Unknown

Indicate below whether the phenotypes were absent, present or not evaluated.

CD4+	Absent	Present	Not evaluated
CD8+	Absent	Present	☐ Not evaluated

Not evaluated 🛛 Unknown